DDInter1325 DDInter1376
A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Ofloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Ofloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Ofloxacin {u} (Compound) binds {v} (Gene) SLC22A4
Ofloxacin {u} (Compound) upregulates {v} (Gene) SELL
Ofloxacin {u} (Compound) palliates {v} (Disease) chronic obstructive pulmonary disease
Ofloxacin {u} (Compound) is included by {v} (Pharmacologic Class) Quinolones
Ofloxacin {u} (Compound) downregulates {v} (Gene) RB1
Ofloxacin {u} (Compound) causes {v} (Side Effect) Petechiae
Ofloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pentostatin
Ofloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Procarbazine
Ofloxacin (Compound) resembles Enoxacin (Compound)
Ofloxacin (Compound) resembles Levofloxacin (Compound)
Ofloxacin (Compound) binds SLC22A4 (Gene)
Ofloxacin (Compound) upregulates SELL (Gene)
Ofloxacin (Compound) palliates chronic obstructive pulmonary disease (Disease)
Ofloxacin (Compound) is included by Quinolones (Pharmacologic Class)
Ofloxacin (Compound) downregulates RB1 (Gene)
Ofloxacin (Compound) causes Petechiae (Side Effect)
Ofloxacin may cause a minor interaction that can limit clinical effects when taken with Pentostatin
Ofloxacin may cause a minor interaction that can limit clinical effects when taken with Procarbazine